Literature DB >> 1384726

The clinical relevance of salivary amylase monitoring in bulimia nervosa.

P Kronvall1, T A Fahy, A Isaksson, S Theander, G F Russell.   

Abstract

The aim of this study was to evaluate the clinical relevance of amylase level monitoring as an objective measure in diagnosis and assessment of treatment response in bulimia nervosa. Thirty-three subjects who fulfilled DSM-111-R criteria for bulimia nervosa had serum levels of total and salivary amylase monitored during an 8-week treatment trial. At the beginning of treatment, the average total amylase level was within the upper limits of normal, whereas average salivary amylase levels were abnormally high. During the course of treatment, there was a significant reduction in the average salivary isoenzyme to within the normal range. Significant reductions in amylase levels were recorded in patients with good treatment outcome, but not in those with poor outcome. Amylase levels were not significantly correlated with severity of bulimic symptoms. These results do not justify the use of amylase assays as a routine diagnostic or monitoring test, but isoenzyme monitoring may provide useful clinical information in selected cases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384726     DOI: 10.1016/0006-3223(92)90018-u

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  3 in total

1.  Anorexia nervosa: Recent research findings and implications for clinical practice.

Authors:  Maria Råstam
Journal:  Eur Child Adolesc Psychiatry       Date:  1994-07       Impact factor: 4.785

2.  Serum amylase in bulimia nervosa and purging disorder: differentiating the association with binge eating versus purging behavior.

Authors:  Barbara E Wolfe; David C Jimerson; Adrian Smith; Pamela K Keel
Journal:  Physiol Behav       Date:  2011-07-18

3.  Alpha-Amylase Activity in Blood Increases after Pharmacological, But Not Psychological, Activation of the Adrenergic System.

Authors:  Urs M Nater; Roberto La Marca; Katja Erni; Ulrike Ehlert
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.